Simple Summary Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known safe level of asbestos exposure. Symptoms of mesothelioma can include worsening breathlessness, chest pain and loss of weight. There is no cure, and the treatment of mesothelioma is limited, although there have been some recent improvements in therapy. Survival is very variable although most people live for around one year after diagnosis. Efforts to improve and maintain the quality of life for patients with mesothelioma remain a priority. Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially considering its limited response to conventional systemic anticancer therapy and that no cure exists. Palliative interventions and support remain paramount with a median survival of 9-12 months after diagnosis. The epidemiology and diagnosis of mesothelioma has been debated over previous decades, due to a number of factors, such as the long latent period following asbestos exposure and disease occurrence, the different potencies of the various forms of asbestos used commercially, the occurrence of mesothelioma in the peritoneal cavity and its heterogeneous pathological and cytological appearances. This review will describe the contemporary knowledge on the epidemiology of mesothelioma and provide an overview of the best clinical practice including diagnostic approaches and management.
机构:
Columbia Univ, Mesothelioma Ctr, New York, NY 10027 USA
Mesothlioma Appl Res Fdn, Washington, DC USAColumbia Univ, Mesothelioma Ctr, New York, NY 10027 USA
Hesdorffer, M. E.
Leinwand, J.
论文数: 0引用数: 0
h-index: 0
机构:
Columbia Univ, New York, NY USAColumbia Univ, Mesothelioma Ctr, New York, NY 10027 USA
Leinwand, J.
Taub, R. N.
论文数: 0引用数: 0
h-index: 0
机构:
Columbia Univ, Med, New York, NY USAColumbia Univ, Mesothelioma Ctr, New York, NY 10027 USA
Taub, R. N.
JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH,
2007,
37
(03):
: 232
-
237
机构:
Royal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Sydney, NSW, AustraliaRoyal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia
Honeyball, Florian
Boyer, Michael
论文数: 0引用数: 0
h-index: 0
机构:
Royal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Sydney, NSW, AustraliaRoyal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia
Boyer, Michael
van Zandwijk, Nico
论文数: 0引用数: 0
h-index: 0
机构:
Asbestos Dis Res Inst, Sydney, NSW, AustraliaRoyal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia
van Zandwijk, Nico
Kao, Steven C.
论文数: 0引用数: 0
h-index: 0
机构:
Royal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia
Asbestos Dis Res Inst, Sydney, NSW, AustraliaRoyal Prince Alfred Hosp, Sydney Canc Ctr, Dept Med Oncol, Sydney, NSW, Australia